10x Genomics downgraded by Guggenheim
$TXG
Biotechnology: Laboratory Analytical Instruments
Industrials
Guggenheim downgraded 10x Genomics from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2025 | Buy → Neutral | Citigroup | |
| 12/2/2025 | $20.00 | Overweight → Equal-Weight | Morgan Stanley |
| 9/11/2025 | $15.00 | Neutral | Piper Sandler |
| 2/13/2025 | $25.00 → $12.00 | Outperform → Market Perform | Leerink Partners |
| 9/3/2024 | $35.00 | Outperform | Leerink Partners |
| 7/22/2024 | $24.00 | Hold → Buy | Jefferies |
| 7/18/2024 | $40.00 → $20.00 | Overweight → Neutral | JP Morgan |
| 7/10/2024 | $55.00 → $25.00 | Buy → Hold | Deutsche Bank |
8-K - 10x Genomics, Inc. (0001770787) (Filer)
SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
Study aims to identify single cell immune signatures of disease activity and treatment response to support clinical care PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced a collaboration with Brigham & Women's Hospital, a world-class academic medical center, to analyze peripheral blood samples from patients living with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and giant cell arteritis (GCA) to uncover immune signatures associated with disease activity, flare, remission and therapeutic response.
Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to power precision oncology 10x also plans to establish a CLIA-certified laboratory to enable development of future innovative diagnostic tests PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progressi
Citigroup downgraded 10x Genomics from Buy to Neutral
Morgan Stanley downgraded 10x Genomics from Overweight to Equal-Weight and set a new price target of $20.00
Piper Sandler initiated coverage of 10x Genomics with a rating of Neutral and set a new price target of $15.00
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Thursday, February 12, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
PLEASANTON, Calif., Nov. 6, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2025. Recent Updates Revenue was $149.0 million for the third quarter, compared to $172.9 million in the second quarter, which included $27.3 million related to one-time license and royalty revenue. Third quarter revenue represents a 2% increase sequentially, excluding the second quarter one-time license and royalty revenue.Started shipping the next-generation of Chromium Flex,
PLEASANTON, Calif., Oct. 9, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer
Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an
Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar
SC 13G - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)